Clinical Report: Accelerated Cancer Treatment Approvals in China (2005-2021)

Overview

This cross-sectional study reviews expedited approval (EA) programs for oncology drugs in China from 2005 to 2021, highlighting regulatory reforms that accelerated drug access. It analyzes review timelines, pivotal trial characteristics, and clinical benefits of approved cancer therapies under EA pathways.

Background

Cancer represents a major health burden globally and in China, which accounts for the highest number of new cancer cases and deaths worldwide. To address urgent unmet medical needs, China implemented expedited approval programs starting in 2005, including Special Approval, Special Review, Priority Review, and Conditional Approval pathways. These programs aim to shorten review times and allow earlier access to innovative cancer therapies, often based on surrogate endpoints. This study evaluates the impact of these regulatory reforms on oncology drug approvals and clinical outcomes.

Data Highlights

The study identified all cancer drugs approved under EA programs for malignant hematology and oncology indications in China from 2005 to 2021 using multiple data sources including the Center of Drug Evaluation annual reports, clinical trial registries, and the Pharnexcloud database. Key data extracted included approval dates, review durations, trial designs, endpoints, and clinical benefit scores using the ESMO-MCBS scale. The analysis encompassed initial and supplemental indications, sponsor nationality, cancer types, and public health insurance classifications.

Key Findings

• China’s EA programs evolved from Special Approval in 2005 to include Priority Review (2015) and Conditional Approval (2017), aligning with FDA and EMA expedited pathways by 2020.
• Between 2005 and 2021, 94 new anticancer drugs were approved primarily through EA programs, reflecting a high proportion of oncology indications among expedited approvals.
• EA pathways enabled shorter review timelines and earlier patient access, with Conditional Approval allowing approval based on less comprehensive data or surrogate endpoints for life-threatening cancers.
• Pivotal clinical trials supporting EA approvals varied in design, with data collected on randomization, blinding, control groups, enrollment, and primary endpoints to assess clinical benefit.
• Clinical benefits of solid tumor drugs approved under EA were evaluated using the ESMO-MCBS, emphasizing therapies that substantially improve survival or quality of life.

Clinical Implications

The implementation of EA programs in China has significantly accelerated the availability of innovative cancer therapies, addressing urgent clinical needs. Clinicians should be aware that some drugs approved under Conditional Approval may rely on surrogate endpoints and require confirmatory trials to verify benefit. Understanding the regulatory context and clinical trial evidence supporting these approvals can guide informed treatment decisions.

Conclusion

China’s expedited approval programs have transformed oncology drug development and access over the past 16 years, facilitating faster review and approval of novel therapies with meaningful clinical benefits. Continued evaluation of these pathways is essential to balance timely access with robust evidence of efficacy and safety.

References

1. Global Cancer Observatory (GLOBOCAN) 2020 -- Cancer Incidence and Mortality Data
2. National Medical Products Administration (NMPA) Annual Reports -- Drug Review and Approval Data
3. European Society for Medical Oncology (ESMO) -- Magnitude of Clinical Benefit Scale